SCHEMBL5701129

SCHEMBL5701129

ClCCCCOc1ccc2ccccc2c1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.66
KDM4E B2RXH2 2/20 0.66
MAPK1 P28482 1/20 0.66
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
AGXT P21549 2/20 0.57
MAPT P10636 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HRH3 Q9Y5N1 7/20 0.55
HDAC1 Q13547 1/20 0.55
HTT P42858 1/20 0.54
ALOX5 P09917 1/20 0.53
DRD3 P35462 1/20 0.53
PPARG P37231 2/20 0.51
PTPN7 P35236 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38652291 1.00 TDP1 (0.66) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL10526722 0.98 TDP1 (0.63) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL5701220 0.94 TDP1 (0.68) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL8565990 0.92 TDP1 (0.76) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL5701247 0.90 TDP1 (0.68) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL31570764 0.90 TDP1 (0.68) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL16902857 0.90 TDP1 (0.73) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL16902870 0.90 TDP1 (0.73) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL16902858 0.90 TDP1 (0.73) TDP1KDM4EMAPK1NPC1RAB9A
SCHEMBL16902850 0.90 TDP1 (0.73) TDP1KDM4EMAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100447126-C Omega substituted naphthyloxy-amino alkane den-ivative used as anti-hyperglycaemia agent and its preparation therefor COUNCIL SCIENT IND RES (IN) 2008-12-31 CN disclosed
CN-1894200-A Omega-substituted naphthyloxy amino alkane derivatives as antihyperglycemic agents and preparation thereof COUNCIL SCIENT IND RES (IN) 2007-01-10 CN disclosed
EP-1682484-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-26 EP disclosed
US-7081465-B2 Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-25 US disclosed
WO-2005042465-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-05-12 WO disclosed
US-20040192688-A1 Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192688-A1 Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders APOB, LIPC, FABP3 TDP1 2757/4885KDM4E 2830/4885MAPK1 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.